Kamada

Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024

Retrieved on: 
Wednesday, February 28, 2024
Eastern Time Zone, KMDA, International, Internet, Kamada

Kamada management will host an investment community conference call on Wednesday, March 6, at 8:30am Eastern Time to discuss these results and answer questions.

Key Points: 
  • Kamada management will host an investment community conference call on Wednesday, March 6, at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel) or 1 201-689-8263 (International) using conference ID 13744277.
  • The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1655132&tp_key=6e560eef4a .
  • The call will also be archived for 90 days on the Company’s website at www.kamada.com.

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Monday, November 13, 2023
Sale, EBITDA, Three Months, Acquisition, Safety, CMV, International, Investment, S&M, SDF, Depreciation, Patient, DSMB, Internet, FDA, G&A, KMDA, Data monitoring committee, Eastern Time Zone, Availability, Innova (video game company), FIMI, Table, R, Growth, Nine Months, Coronavirus Scientific Advisory Board, TASE, Immunoglobulin G, Clothing, Pharmaceutical industry, Fine chemical, Security (finance), Video game, Reinsurance, Kamada

“Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.

Key Points: 
  • “Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.
  • Financial Highlights for the Three Months Ended September 30, 2023
    Total revenues were $37.9 million in the third quarter of 2023, an 18% increase from the $32.2 million recorded in the third quarter of 2022.
  • S&M costs, for the third quarter of 2023 and 2022, included $0.4 million of depreciation expenses of intangible assets generated through the IgG products acquisition.
  • Kamada continues to expect to generate fiscal year 2023 total revenues in the range of $138 million to $146 million.

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

Retrieved on: 
Wednesday, November 8, 2023
TASE, Eastern Time Zone, International, KMDA, Kamada, Internet

Kamada management will host an investment community conference call on Monday, November 13, at 8:30am Eastern Time to discuss these results and answer questions.

Key Points: 
  • Kamada management will host an investment community conference call on Monday, November 13, at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel) or 1 201-689-8263 (International) using conference ID 13741701.
  • The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1637192&tp_key=fd85a910fe .
  • The call will also be archived for 90 days on the Company’s website at www.kamada.com.

Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

Retrieved on: 
Monday, October 16, 2023
Transfer, Kamada, Food, Division, CSL Behring, Research, University of Texas Southwestern Medical Center, Pancreas, Cytomegalovirus, Critical care, Liver, Heart, Holocene, Immunoglobulin G, Safety, University, Transplant, Survival, Tobacco Products Scientific Advisory Committee, FDA, Kidney, Food and Drug Administration, Lung, Availability, KMDA, TASE, Patient, CMV, Pharmaceutical industry

Kamada announced that CYTOGAM manufactured at the Company’s facility in Beit Kama, Israel, is now available for commercial sales in the U.S.

Key Points: 
  • Kamada announced that CYTOGAM manufactured at the Company’s facility in Beit Kama, Israel, is now available for commercial sales in the U.S.
  • This follows the recent FDA approval of the technology transfer process of CYTOGAM from its previous manufacturer, CSL Behring.
  • The availability of Kamada-manufactured CYTOGAM in Canada is expected later this year.
  • The advisory board focuses on Kamada’s newly implemented U.S. clinical program for CYTOGAM including new opportunities and future research and development possibilities.

Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

Retrieved on: 
Wednesday, August 30, 2023
Private law, Private, United Kingdom company law, Record, Exchange, KMDA, Doctor of Philosophy, Sale, Regenerative medicine, Private placement, Growth planning, FIMI, Prospectus, Kamada, TASE, Growth, Pursuit, Risk management, Management, Security (finance), MD

Under the terms of the Private Placement, Kamada will be issuing an aggregate of approximately 12.6 million ordinary shares to FIMI at a price of $4.75 per share (which represented the average closing price of the Company’s shares on NASDAQ during the 20 trading days prior to the date of execution of the Private Placement).

Key Points: 
  • Under the terms of the Private Placement, Kamada will be issuing an aggregate of approximately 12.6 million ordinary shares to FIMI at a price of $4.75 per share (which represented the average closing price of the Company’s shares on NASDAQ during the 20 trading days prior to the date of execution of the Private Placement).
  • Upon closing of the Private Placement, expected during the first week of September, FIMI will beneficially own approximately 38% of Kamada’s outstanding ordinary shares and will become a controlling shareholder of the Company, within the meaning of the Israeli Companies Law, 1999 (the "Companies Law").
  • “We are grateful for the support of FIMI and our shareholders in approving the $60 million private placement,” said Amir London, Kamada’s Chief Executive Officer.
  • Any offering of the ordinary shares under the resale registration statement will only be by means of a prospectus.

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Wednesday, August 16, 2023
Loss, International, Table, SDF, Eastern Time Zone, European Medicines Agency, Innova (video game company), G&A, KMDA, Action Replay, EMA, Internet, FIMI, EBITDA, Kamada, Acquisition, Investment, TASE, Immunoglobulin G, Depreciation, Growth, R, Adjustment, FDA, S&M, Second Half, Three Months, FEV1, Fiscal, Video game, Security (finance), Fine chemical, Pharmaceutical industry, Tutoring, Bookkeeping, Cryptocurrency

“Our strong start to 2023 continued in the second quarter, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.

Key Points: 
  • “Our strong start to 2023 continued in the second quarter, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.
  • Financial Highlights for the Three Months Ended June 30, 2023
    Total revenues were $37.4 million in the second quarter of 2023, a 59% increase from the $23.6 million recorded in the second quarter of 2022.
  • Gross profit and gross margins were $14.4 million and 39%, respectively, in the second quarter of 2023, compared to $7.2 million and 31%, respectively, reported in the second quarter of 2022.
  • Adjusted EBITDA, as detailed in the tables below, was $6.0 million in the second quarter of 2023, as compared to $1.3 million in the second quarter of 2022.

Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023

Retrieved on: 
Wednesday, August 9, 2023
Internet, Eastern Time Zone, International, Kamada, KMDA, TASE, Rare-earth element, Internet service provider, Bank

REHOVOT, Israel and HOBOKEN, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2023, prior to the open of the U.S. financial markets on Wednesday, August 16, 2023.

Key Points: 
  • REHOVOT, Israel and HOBOKEN, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2023, prior to the open of the U.S. financial markets on Wednesday, August 16, 2023.
  • Kamada management will host an investment community conference call on Wednesday, August 16, 2023 at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel) or 1 201-689-8263 (International) using conference ID 13740401.
  • The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1626943&tp_key=6e37fa90e3 .

Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

Retrieved on: 
Wednesday, May 24, 2023
Workforce, International, Increase, Emphysema, General counsel, Table, DSMB, Bank statement, St Saviour's and St Olave's Church of England School, Food, Innova (video game company), G&A, KMDA, Data monitoring committee, Internet, AATD, FIMI, EBITDA, Kamada, Samsung Galaxy Note 5, Acquisition, Patient, Annual report, Investment, TASE, Corporation, Immunoglobulin G, CFO, Depreciation, Growth, AAT, R, Security (finance), FDA, S&M, Three Months, Video game, Pharmaceutical industry, Fine chemical, Insurance

“We are off to an excellent start to 2023, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.

Key Points: 
  • “We are off to an excellent start to 2023, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.
  • “As such, we are reiterating our full-year 2023 revenue guidance of $138 million to $146 million and EBITDA guidance of $22 million to $26 million, which would represent profitability growth of over 30% as compared to 2022.
  • During the first quarter of 2023, Kamada conducted a planned workforce downsizing at its Israeli plant, optimizing staff level to its capacity needs.
  • Kamada continues to expect to generate fiscal year 2023 total revenues in the range of $138 million to $146 million.

Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds

Retrieved on: 
Wednesday, May 24, 2023
FBC, Purchasing, Private, Morrison, Exchange, KMDA, Sale, Private placement, FIMI, Prospectus, Sales management, TASE, Asset purchase agreement, Growth, Roni, Morrison & Foerster, Security (finance), Stifel, Kamada, Incorporated

Proceeds from the Private Placement are expected to be used to support the Company’s growth plans and execution of strategic business development opportunities.

Key Points: 
  • Proceeds from the Private Placement are expected to be used to support the Company’s growth plans and execution of strategic business development opportunities.
  • “This $60 million private placement is indicative of the confidence FIMI has in Kamada’s significant growth potential,” said Amir London, Kamada’s Chief Executive Officer.
  • The special committee received fairness opinions from financial advisors regarding the terms of the Private Placement and retained its own legal counsel.
  • The securities offered under the Private Placement have not been registered under the Securities Act of 1933, as amended.

Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023

Retrieved on: 
Wednesday, May 17, 2023
Internet, Eastern Time Zone, International, Kamada, KMDA, TASE, Rare-earth element, Internet service provider, Bank

REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2023, prior to the open of the U.S. financial markets on Wednesday, May 24, 2023.

Key Points: 
  • REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2023, prior to the open of the U.S. financial markets on Wednesday, May 24, 2023.
  • Kamada management will host an investment community conference call on Wednesday, May 24, at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.) or 1 201-689-8263 (International) using conference ID 13738719.
  • The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1614685&tp_key=87fb1414ee .